Zim Laboratories Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹731 Cr
- P/E
- 197.52
- ROE
- 1.59%
- PEG
- -4.52
- Price to sales
- 1.85
- Debt to equity
- 0.43
- 52W high / low
- ₹153 / ₹60.3
- Sales growth (5Y)
- 4.03%
- EBITDA margin
- 7.11%
- Net profit margin
- 1.16%
- Promoter holding
- 30.30%
- Sales (last year)
- ₹397 Cr
Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India[1]
Guidance scorecard · Q1 FY27 call
What Zim Laboratories Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires.
- FY28 growth expected at 30-40% if EU-GMP certification is obtained, with major value unlock from EU market entry.
- Revenue projection for FY28 around INR 500 crores subject to EU-GMP certification.
- Sales from innovative product portfolio and regulated market (NIP and Oral Thin Film) expected to contribute significantly post EU-GMP.
- Growth driven by expansion into regulated markets, new product launches, and improved organizational capabilities.
- Lag of about two quarters expected between EU-GMP certification and start of substantial supply and revenue impact.
2 more points from Zim Laboratories Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Zim Laboratories Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- CapEx for FY27 is mostly completed.
- Remaining CapEx mainly involves normal upgradation expenses.
- Planned CapEx of around INR 15-20 crores to upgrade the enzyme plant and Nutra plant.
2 more points from Zim Laboratories Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Zim Laboratories Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- The company has mentioned having 8 to 10 Market Authorizations (MAs) awaiting activation once EU-GMP certification is obtained.
- Some products are already being produced at alternate facilities as a risk mitigation measure.
- Inventory buildup is selective, focused on APIs for key products with longer lead times; other inventory is managed on a just-in-time basis.
- Orders from Australia have started, with supplies expected to begin within 2-3 months pending TGA certification.
2 more points from Zim Laboratories Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Zim Laboratories Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Zim Laboratories Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Zim Laboratories Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 105.41 | 67.44 | 85.83 | 96.29 | 117.86 | 81.82 | 92.14 | 96.33 | 108.73 | 71.76 | 88.71 | 108.66 | 105.27 |
| Expenses + | 89.96 | 62.62 | 76.50 | 84.75 | 102.21 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 |
| Operating Profit | 15.45 | 4.82 | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.60 | 4.25 | 5.76 | 12.81 | 7.19 |
| OPM % | 14.66% | 7.15% | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% |
| Other Income + | 0.69 | 1.12 | 1.42 | 1.11 | 1.53 | 1.00 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.70 | 6.16 |
| Interest | 1.27 | 1.73 | 1.22 | 1.70 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.30 | 3.16 | 3.43 | 3.31 |
| Depreciation | 4.93 | 4.03 | 4.09 | 3.94 | 3.91 | 4.94 | 5.00 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.10 |
| Profit before tax | 9.94 | 0.18 | 5.44 | 7.01 | 10.99 | 1.24 | 2.96 | 5.70 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 |
| Tax % | 27.16% | -22.22% | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% |
| Net Profit + | 7.24 | 0.23 | 4.15 | 4.78 | 8.09 | 0.90 | 2.38 | 4.00 | 4.88 | -1.87 | -0.42 | 4.40 | 3.74 |
| EPS in Rs | 1.49 | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 |
Financials of Zim Laboratories Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 |
| Expenses + | 278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 |
| Operating Profit | -12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 |
| OPM % | -4% | 11% | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 11% | 12% | 8% |
| Other Income + | 2 | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 5 | 6 | 11 |
| Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 |
| Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 |
| Profit before tax | -27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 |
| Tax % | -19% | 5% | -6% | 23% | 30% | -4,600% | 28% | 31% | 31% | 27% | 32% | 29% |
| Net Profit + | -22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 |
| EPS in Rs | 3.17 | 0.68 | 1.50 | 2.99 | 5.01 | 3.54 | 2.50 | 1.09 | ||||
| Dividend Payout % | 0% | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Zim Laboratories Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 |
| Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 |
| Borrowings + | 93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 126 |
| Other Liabilities + | 78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 118 |
| Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Fixed Assets + | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 199 |
| CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 59 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 |
| Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
Financials of Zim Laboratories Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 | |
| Cash from Investing Activity + | -12 | -7 | -26 | -21 | -19 | -6 | -14 | -36 | -73 | -40 | -56 | |
| Cash from Financing Activity + | -10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 | -9 | 28 | |
| Net Cash Flow | -0 | -0 | 1 | -1 | 1 | -0 | 2 | 3 | 3 | -8 | 21 | |
| Free Cash Flow | 9 | 24 | 8 | 15 | 3 | 25 | 34 | 2 | -57 | 1 | 11 | |
| CFO/OP | 77% | 109% | 117% | 85% | 119% | 83% | 121% | 87% | 46% | 92% | 165% |
Financials of Zim Laboratories Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 120 | 137 | 119 | 101 | 89 | 86 | 98 | 87 | 100 | 103 | 106 |
| Inventory Days | 93 | 87 | 108 | 134 | 126 | 144 | 125 | 171 | 99 | 173 | 188 | 207 |
| Days Payable | 129 | 109 | 137 | 172 | 165 | 168 | 149 | 185 | 107 | 133 | 151 | 161 |
| Cash Conversion Cycle | 75 | 99 | 108 | 81 | 63 | 65 | 62 | 85 | 79 | 140 | 140 | 152 |
| Working Capital Days | 38 | 34 | 54 | 37 | 39 | 46 | 49 | 67 | 67 | 57 | 60 | 41 |
| ROCE % | 13% | 14% | 14% | 15% | 5% | 11% | 12% | 17% | 10% | 8% | 5% |
Guidance history
How Zim Laboratories Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | None planned | Planned | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | Planned | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
89 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +65.3% | 89% |
| Last 6 months | +55.3% | 90% |
| Last 3 months | +22.5% | 88% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Zim Laboratories Ltd: 0.4 × 89 + 0.4 × 90 + 0.2 × 88 = 89.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Zim Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY